FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a “market perform” rating on shares of FibroGen in a research note on Monday, June 3rd.

FibroGen Price Performance

Shares of NASDAQ:FGEN opened at $0.38 on Friday. The company has a market capitalization of $37.57 million, a PE ratio of -0.15 and a beta of 0.71. The business has a fifty day moving average price of $0.86 and a two-hundred day moving average price of $1.37. FibroGen has a 1 year low of $0.33 and a 1 year high of $2.93.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. The business had revenue of $50.64 million during the quarter, compared to the consensus estimate of $33.00 million. During the same quarter last year, the company earned ($0.65) EPS. Sell-side analysts anticipate that FibroGen will post -1.05 earnings per share for the current year.

Insider Buying and Selling at FibroGen

In other FibroGen news, insider Deyaa Adib purchased 22,123 shares of the stock in a transaction on Wednesday, June 12th. The shares were purchased at an average price of $1.17 per share, with a total value of $25,883.91. Following the acquisition, the insider now directly owns 82,123 shares in the company, valued at approximately $96,083.91. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 1.98% of the company’s stock.

Hedge Funds Weigh In On FibroGen

A number of large investors have recently modified their holdings of FGEN. Alpine Global Management LLC purchased a new position in shares of FibroGen during the 1st quarter valued at about $25,000. Delap Wealth Advisory LLC purchased a new position in FibroGen in the 1st quarter worth approximately $27,000. Point72 DIFC Ltd increased its stake in FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares during the period. Doheny Asset Management CA purchased a new position in FibroGen in the 2nd quarter worth approximately $48,000. Finally, Accel Wealth Management increased its stake in FibroGen by 117.5% in the 2nd quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 51,645 shares during the period. 72.71% of the stock is owned by hedge funds and other institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.